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Introduction
In this article the term ‘neoadjuvant’ is used to describe pre-
operative treatment for 3 months or more for large (usually
≥3 cm) operable cancers before surgery. Clinical response
and pathological response are important end-points. The term
‘presurgical’ refers to treatment of short duration (around
2 weeks) before surgery, sometimes referred to as a ‘window
of opportunity’ study. This approach can be used for any size
of cancer provided it can be core biopsied, and the end-
points are molecular markers.
Traditional goals of neoadjuvant therapy include the following:
￿ to improve survival;
￿ to downstage so that inoperable cancers become operable
or so that conservative surgery can replace mastectomy;
￿ to identify short-term clinical or molecular markers of
response to predict long-term outcome as a prelude to (or
as a substitute for) adjuvant trials;
￿ to predict outcome and plan further treatment in the
individual patient; and
￿ to identify the molecular mechanisms that underlie
response and resistance to treatment.
Short-term presurgical therapies can have similar aims with
the proviso being that this treatment will not lead to
downstaging and that clinical and pathological response
rates are unrealistic end-points.
Current evidence suggests that there is no survival benefit
from neoadjuvant chemotherapy [1]. The question has not
thus far been addressed in a large neoadjuvant endocrine
therapy trial. Neoadjuvant chemotherapy has been shown to
downstage and reduce the need for mastectomy in some but
by no means all women [1]. The same is true for neoadjuvant
endocrine therapy; about 40% of mastectomies can be
avoided with preoperative aromatase inhibitor therapy [2].
Short-term surrogate clinical and
pathological markers for outcome
Clinical response
Clinical response is widely used as a primary or secondary
end-point in current neoadjuvant chemotherapy trials
(Table 1). This, however, is misguided.
In our own series of 995 patients treated with neoadjuvant
chemotherapy at the Royal Marsden Hospital, London, over
the past 15 years, there was no significant correlation
between clinical response (including clinical complete
remission) and long-term disease-free survival or overall
survival. Similar findings were reported for the National
Surgical Adjuvant Breast and Bowel Project (NSABP)B-18
trial, in which 1,500 patients were randomly assigned to
receive neoadjuvant or adjuvant chemotherapy [3]. In the
subsequent NSABPB-27 trial, which involved almost 2,500
patients, neoadjuvant adriamycin/cyclophosphamide (AC)
alone, four courses, was compared with the same treatment
followed by docetaxel for four courses prior to surgery. The
sequential arm achieved a significantly higher complete
clinical remission rate than AC alone (64% versus 40%;
P < 0.001) but there was no significant difference in
survival [4,5].
In our own experience, neoadjuvant chemotherapy involving
cisplatin or carboplatin achieved a significantly higher
complete clinical remission rate in patients with triple
negative breast cancer than in others (88% versus 51%;
P < 0.005), but there was no improvement in overall survival,
and indeed the triple negative group exhibited a trend toward
inferior survival [6].
A clinical response to neoadjuvant chemotherapy is therefore
encouraging for the doctor and the patient, but its prognostic
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A similar uncertainty exists for neoadjuvant endocrine therapy.
Neoadjuvant letrozole was shown in a randomized trial to
achieve a higher clinical response rate than neoadjuvant
tamoxifen [7], and a large similar adjuvant trial, the Breast
International Group 1-98 trial [8], confirmed superior long-
term outcome for letrozole over tamoxifen. In contrast, the
Immediate Preoperative Anastrozole Tamoxifen or Combined
with Tamoxifen (IMPACT) trial, which compared neoadjuvant
anastrozole versus tamoxifen versus the combination, found
no significant difference in complete response [2], whereas
the identical treatments in the large adjuvant Anastrozole,
Tamoxifen, Alone or in Combination (ATAC) trial [9] identified
a long-term benefit for anastrozole.
Likewise, in both these neoadjuvant trials the aromatase
inhibitors letrozole and anastrozole were each very selectively
superior to tamoxifen in terms of clinical response in tumours
that were human epidermal growth factor receptor (HER)-2
positive [2,10], yet this selective benefit was not seen in
either of the respective adjuvant trials in patients with HER-2-
positive cancer.
Pathological complete remission
In contrast to clinical response, pathological complete
remission (pathCR) is well established as being associated
with significantly improved outcome. The problem with this
end-point is that it is late, and it is available only at the time of
surgery after neoadjuvant therapy has been completed. In
addition, it is achieved only in a minority of patients, usually
around 10% to 15%, with neoadjuvant chemotherapy in large
series, and is extremely rare with neoadjuvant endocrine
therapy, occurring in 1% of patients or fewer.
Furthermore, pathCR does not always correlate with improved
outcome. In the Royal Marsden Series we found no
correlation between pathCR and improved outcome in
patients with oestrogen receptor positive cancers [11].
Likewise, in a recent study based on molecular subtypes, the
highest pathCR rate of 29% was seen in basal-like breast
cancers, as compared with only 6.5% in luminal cancers; in
contrast, luminal cancers had a significantly better long-term
outcome than did basal-like cancers [12].
In the NSABPB-27 trial described above, the sequential
combination of AC followed by docetaxel achieved a signifi-
cantly higher pathCR rate than did AC alone (26% versus
13%;  P < 0.001), yet no survival difference was seen
between the two arms.
PathCR rate is widely used as a primary or secondary end-
point in current neoadjuvant chemotherapy trials (Table 1),
but its correlation with improved outcome, although frequent,
is not always seen.
Molecular markers: Ki67
In the IMPACT neoadjuvant endocrine therapy trial referred to
above, the percentage reduction in the proliferation marker Ki67
at 2 weeks after starting treatment, compared with baseline,
was significantly greater for anastrozole than for tamoxifen or the
combination [13]. This exactly predicted the outcome of the
Taxotere as Adjuvant Chemotherapy Trial (TACT), suggesting
that a short-term change in this important proliferation marker
could predict long-term outcome in clinical trials.
Long-term outcome from the same neoadjuvant trial revealed
that the Ki67 level in the individual tumour 2 weeks after
starting endocrine therapy predicted long-term outcome and
was a more effective predictor than baseline Ki67 [14]. If
confirmed, then Ki67 at 2 weeks after starting endocrine
therapy could predict outcome in the individual patient and
could be used to determine who might need further adjuvant
therapy (and in particular adjuvant chemotherapy) and who
would not.
This hypothesis is being tested in the large UK national trial
POETIC (PreOperative Endocrine Therapy: Individualising
Care). In this trial 4,000 postmenopausal women with hormone
receptor positive breast cancer will be randomly assigned to
2 weeks of preoperative aromatase inhibitor or to no
preoperative treatment. The first end-point of the trial will be
relapse-free survival, determining whether this approach
might have a long-term outcome benefit. The second aim is to
validate whether 2-week Ki67 (measured at the time of
excision surgery) does indeed predict long-term outcome in
the individual patient. The third aim is to determine whether
multiple changes in gene expression after 2 weeks of treat-
ment with an aromatase inhibitor may provide further insight
into the prediction of long-term outcome and into mecha-
nisms of response and resistance to endocrine therapy.
In our own experience with neoadjuvant chemotherapy at the
Royal Marsden, we have shown that the level of Ki67 in the
Table 1
End-points in current neoadjuvant chemotherapy trials
Trial n Primary end-point Secondary end-point
GEPARDUO 913 Clinical OR PathCR
NeoTANGO 800 PathCR Clinical OR
NSABPB-40 1,200 PathCR Clinical OR
GEPAR4 1,500 PathCR Clinical OR
NOAH 288 PathCR Clinical OR
PREPARE 733 DFS PathCR
AGO 679 PathCR Clinical OR
neoALTTO 450 PathCR Clinical OR
Presented are some current neoadjuvant chemotherapy trials using
clinical response and pathCR as primary or secondary end-points.
DFS, disease-free survival; OR, overall response; pathCR, pathological
complete remission.Page 3 of 3
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excision biopsy after 4 months of chemotherapy likewise
predicts long-term outcome in the individual patient [15]. This
raises the important question of whether a similar change
after one course of chemotherapy would predict long-term
outcome. If so, then this could be used as a basis for
continuing effective chemotherapy or discontinuing ineffective
treatment after one course in the individual patient.
Conclusion
Neoadjuvant chemotherapy and endocrine therapy trials are
only appropriate for a minority of patients with large cancers,
and their current standard end-points - pathCR and clinical
response - are inconsistent in predicting long-term outcome.
Their value is therefore limited, although the clinical benefit of
neoadjuvant therapy in downstaging to avoid mastectomy
remains valid.
In contrast, short-duration presurgical trials are applicable to
many more patients, including those with smaller cancers,
and the study of molecular marker changes in such trials may
provide information valuable to efforts to individualise
adjuvant treatment.
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